Schizophrenia
Conditions
Keywords
Schizophrenia, Risperidone, Risperdal consta
Brief summary
The purpose of this study is to evaluate efficacy, safety and tolerance of long-acting risperidone when switching from oral antipsychotics in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self).
Detailed description
This is an open-label (all people know the identity of the intervention), multi-centric (conducted in more than one center) and non-comparative study of long-acting risperidone in participants with schizophrenia who have a previous history (in the last 12 months) of bad adherence to the oral antipsychotic treatment of first or second generation. The duration of this study will be 24 weeks and will include following visits: Screening, Baseline, Week 2, 4, 8, 12, 16, 20, 24, 38 and 50 (End visit or early withdrawal). All the eligible participants (after risperidone intolerance test during screening) will receive a dose of 25 milligram risperidone every two weeks by intramuscular injection (injection of a substance into a muscle). Efficacy and safety of the participants will primarily be evaluated by Positive and Negative Syndromes Scale and Extrapyramidal Symptom Rating Scale, respectively. Participants' safety will be monitored throughout the study.
Interventions
DRUGRisperidone prolonged release
Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
Sponsors
Janssen-Cilag Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Have schizophrenia diagnosis by Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) * Be on treatment with oral antipsychotic of first or second generation, for a minimum time of 12 months * Previous history of bad adhesion to oral antipsychotic treatment in the last 12 months * Total Positive and Negative Syndrome Scale score less than or equal to 90, the conceptual disorganization, hallucinatory behavior, suspicion and not usual content of thought must be less than or equal to 4 * Be not pregnant as showed on negative pregnancy serum test
Exclusion criteria
* Contraindication or known hypersensitivity to risperidone * Previous history of unsatisfactory response to risperidone * Previous history of refractivity to the other second generation antipsychotics * Use of antipsychotic of intramuscular deposit in the last 12 months * Other mental disturbances of DSM-IV axis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Positive and Negative Syndromes Scale (PANSS) Total Score at Week 50 | Week 50 | The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening. |
| Positive and Negative Syndromes Scale (PANSS) Total Score at Week 2 | Week 2 | The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening. |
| Positive and Negative Syndromes Scale (PANSS) Total Score at Week 4 | Week 4 | The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening. |
| Positive and Negative Syndromes Scale (PANSS) Total Score at Week 8 | Week 8 | The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening. |
| Positive and Negative Syndromes Scale (PANSS) Total Score at Week 16 | Week 16 | The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening. |
| Positive and Negative Syndromes Scale (PANSS) Total Score at Week 24 | Week 24 | The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening. |
| Positive and Negative Syndromes Scale (PANSS) Total Score at Week 38 | Week 38 | The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Extrapyramidal Symptoms Rating Scale (ESRS) Total Score | Baseline and Week 2, 4, 8, 16, 24 and 50 | The ESRS is used to assess four types of drug-induced movement disorders administered as a questionnaire. Score range from 0 to 6 (0 is absent and 6 is extremely severe). |
| Drug Attitude Inventory (DAI-10) | Screening, and Week 8, 24 and 50 | The DAI-10 is a 10-item questionnaire to assess 1) subjective experience of drug and 2) attitudes and beliefs toward neuroleptics which may influence compliance in schizophrenia participants. It is the binary scale assessing the participant's subjective response. A 'compliant' response is scored as +1; a dysphoric response is scored as -1. A positive sum of items indicates a positive subjective response (SR); a negative sum of scores indicates a negative SR (non-compliant). The final score is the grand total of the positive and negative points. Total score ranges from (-) 10 to (+) 10, higher score indicates positive SR (compliant) and lower score indicates negative SR (non-compliant). |
| Short Form-36 (SF-36) - Quality of Life | Baseline and Week 50 | The SF-36 is a survey of participant health. It consists of eight scaled scores, which are the weighted sums of the questions in their section. The eight sections are: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Each item is scored on a 0-100 range so that the lowest and highest possible scores are set at 0 and 100, respectively. All items are scored so that a high score defines a more favorable health state. |
| Personal and Social Performance (PSP) Scale Score | Screening, and Week 8, 16, 24, 38 and 50 | The PSP scale assesses the degree of a participant's dysfunction (ranging from i \[absent\] to vi \[very severe) within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, disturbing and aggressive behavior. The overall score ranges from 1 to 100. Based on the 4-domains there was one total score. Participants with a score of 71 to 100 had a mild degree of difficulty; from 31 to 70, varying degrees of disability; participants with scores of 30 or less function so poorly as to require intensive supervision. |
| Global Assessment of Functioning (GAF) Scale Score | Screening, and Week 8, 16, 24, 38 and 50 | The GAF scale is a 100-point tool rating overall psychological, social and occupational functioning of adults. The higher score range (91-100) refers to a superior functioning in a wide range of activities, and absence of symptoms. The lower score range (1-10) refers to persistent danger of severely hurting self or others; or persistent inability to maintain minimum personal hygiene; or serious suicidal act with clear expectation of death. |
| Clinical Global Impressions (CGI) - Disease Severity Score | Baseline and Week 2, 4, 8, 16, 24, 38 and 50 | The CGI rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 indicates to normal, not at all ill and a rating of 7 indicates among the most extremely ill participants. Higher scores indicate worsening. |
Countries
Brazil
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Risperidone Prolonged Release Risperidone was administered as an intramuscular injection (injection of a substance into a muscle) at a dose of 25 milligram (mg), every two weeks, from Week 1 to 50, wherein after Week 3, dose was adjusted up to 50 mg at Physician criterion. For first two weeks, previous oral antipsychotic drug was maintained and the dose was gradually decreased and ceased at Week 3. | 53 |
| Total | 53 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 4 |
| Overall Study | Exacerbation of psychotic symptoms | 1 |
| Overall Study | Lost to Follow-up | 2 |
| Overall Study | Withdrawal by Subject | 15 |
Baseline characteristics
| Characteristic | Risperidone Prolonged Release |
|---|---|
| Age, Continuous | 33.6 Years STANDARD_DEVIATION 9.1 |
| Positive and Negative Syndromes Scale (PANSS) Total Score | 58.80 Units on a scale STANDARD_DEVIATION 1.82 |
| Sex: Female, Male Female | 14 Participants |
| Sex: Female, Male Male | 39 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 40 / 53 |
| serious Total, serious adverse events | 3 / 53 |
Outcome results
Primary
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 16
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
Time frame: Week 16
Population: The ITTe population included all the Participants who received at least one dose of study medication and provided one measure post-baseline of efficacy.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Risperidone Prolonged Release | Positive and Negative Syndromes Scale (PANSS) Total Score at Week 16 | 50.55 Units on a scale | Standard Error 1.98 |
Primary
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 2
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
Time frame: Week 2
Population: Intent-to-treat-efficacy evaluation (ITTe) population included all the Participants who received at least one dose of study medication and provided one measure post-baseline of efficacy.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Risperidone Prolonged Release | Positive and Negative Syndromes Scale (PANSS) Total Score at Week 2 | 55.53 Units on a scale | Standard Error 1.82 |
Primary
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 24
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
Time frame: Week 24
Population: The ITTe population included all the Participants who received at least one dose of study medication and provided one measure post-baseline of efficacy.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Risperidone Prolonged Release | Positive and Negative Syndromes Scale (PANSS) Total Score at Week 24 | 48.95 Units on a scale | Standard Error 2.13 |
Primary
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 38
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
Time frame: Week 38
Population: The ITTe population included all the Participants who received at least one dose of study medication and provided one measure post-baseline of efficacy.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Risperidone Prolonged Release | Positive and Negative Syndromes Scale (PANSS) Total Score at Week 38 | 47.40 Units on a scale | Standard Error 2.26 |
Primary
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 4
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
Time frame: Week 4
Population: The ITTe population included all the Participants who received at least one dose of study medication and provided one measure post-baseline of efficacy.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Risperidone Prolonged Release | Positive and Negative Syndromes Scale (PANSS) Total Score at Week 4 | 53.82 Units on a scale | Standard Error 1.83 |
Primary
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 50
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
Time frame: Week 50
Population: The ITTe population included all the Participants who received at least one dose of study medication and provided one measure post-baseline of efficacy.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Risperidone Prolonged Release | Positive and Negative Syndromes Scale (PANSS) Total Score at Week 50 | 49.72 Units on a scale | Standard Error 2.32 |
Primary
Positive and Negative Syndromes Scale (PANSS) Total Score at Week 8
The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.
Time frame: Week 8
Population: The ITTe population included all the Participants who received at least one dose of study medication and provided one measure post-baseline of efficacy.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Risperidone Prolonged Release | Positive and Negative Syndromes Scale (PANSS) Total Score at Week 8 | 51.28 Units on a scale | Standard Error 1.86 |
Secondary
Clinical Global Impressions (CGI) - Disease Severity Score
The CGI rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 indicates to normal, not at all ill and a rating of 7 indicates among the most extremely ill participants. Higher scores indicate worsening.
Time frame: Baseline and Week 2, 4, 8, 16, 24, 38 and 50
Population: The ITTe population included all the Participants who received at least one dose of study medication and provided one measure post-baseline of efficacy.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Risperidone Prolonged Release | Clinical Global Impressions (CGI) - Disease Severity Score | Baseline | 3.55 Units on a scale | Standard Error 0.13 |
| Risperidone Prolonged Release | Clinical Global Impressions (CGI) - Disease Severity Score | Week 2 | 3.37 Units on a scale | Standard Error 0.13 |
| Risperidone Prolonged Release | Clinical Global Impressions (CGI) - Disease Severity Score | Week 4 | 3.30 Units on a scale | Standard Error 0.13 |
| Risperidone Prolonged Release | Clinical Global Impressions (CGI) - Disease Severity Score | Week 8 | 3.21 Units on a scale | Standard Error 0.13 |
| Risperidone Prolonged Release | Clinical Global Impressions (CGI) - Disease Severity Score | Week 16 | 3.10 Units on a scale | Standard Error 0.14 |
| Risperidone Prolonged Release | Clinical Global Impressions (CGI) - Disease Severity Score | Week 24 | 2.92 Units on a scale | Standard Error 0.15 |
| Risperidone Prolonged Release | Clinical Global Impressions (CGI) - Disease Severity Score | Week 38 | 2.94 Units on a scale | Standard Error 0.15 |
| Risperidone Prolonged Release | Clinical Global Impressions (CGI) - Disease Severity Score | Week 50 | 3.19 Units on a scale | Standard Error 0.16 |
Secondary
Drug Attitude Inventory (DAI-10)
The DAI-10 is a 10-item questionnaire to assess 1) subjective experience of drug and 2) attitudes and beliefs toward neuroleptics which may influence compliance in schizophrenia participants. It is the binary scale assessing the participant's subjective response. A 'compliant' response is scored as +1; a dysphoric response is scored as -1. A positive sum of items indicates a positive subjective response (SR); a negative sum of scores indicates a negative SR (non-compliant). The final score is the grand total of the positive and negative points. Total score ranges from (-) 10 to (+) 10, higher score indicates positive SR (compliant) and lower score indicates negative SR (non-compliant).
Time frame: Screening, and Week 8, 24 and 50
Population: ITTs population included all the Participants who received at least one dose of study medication and were reassessed after the start of use. 'N' (number of participants analyzed) signifies the participants evaluable for this measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Risperidone Prolonged Release | Drug Attitude Inventory (DAI-10) | Screening | 2.78 Units on a scale | Standard Error 0.62 |
| Risperidone Prolonged Release | Drug Attitude Inventory (DAI-10) | Week 8 | 4.45 Units on a scale | Standard Error 0.64 |
| Risperidone Prolonged Release | Drug Attitude Inventory (DAI-10) | Week 24 | 4.59 Units on a scale | Standard Error 0.69 |
| Risperidone Prolonged Release | Drug Attitude Inventory (DAI-10) | Week 50 | 5.07 Units on a scale | Standard Error 0.77 |
Secondary
Extrapyramidal Symptoms Rating Scale (ESRS) Total Score
The ESRS is used to assess four types of drug-induced movement disorders administered as a questionnaire. Score range from 0 to 6 (0 is absent and 6 is extremely severe).
Time frame: Baseline and Week 2, 4, 8, 16, 24 and 50
Population: Intent-to-treat-safety evaluation (ITTs) population included all the Participants who received at least one dose of study medication and were reassessed after the start of use. 'N' (number of participants analyzed) signifies the participants evaluable for this measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Risperidone Prolonged Release | Extrapyramidal Symptoms Rating Scale (ESRS) Total Score | Baseline | 0.460 Units on a scale | Standard Error 0.073 |
| Risperidone Prolonged Release | Extrapyramidal Symptoms Rating Scale (ESRS) Total Score | Week 2 | 0.416 Units on a scale | Standard Error 0.072 |
| Risperidone Prolonged Release | Extrapyramidal Symptoms Rating Scale (ESRS) Total Score | Week 4 | 0.272 Units on a scale | Standard Error 0.073 |
| Risperidone Prolonged Release | Extrapyramidal Symptoms Rating Scale (ESRS) Total Score | Week 8 | 0.289 Units on a scale | Standard Error 0.074 |
| Risperidone Prolonged Release | Extrapyramidal Symptoms Rating Scale (ESRS) Total Score | Week 16 | 0.271 Units on a scale | Standard Error 0.079 |
| Risperidone Prolonged Release | Extrapyramidal Symptoms Rating Scale (ESRS) Total Score | Week 24 | 0.221 Units on a scale | Standard Error 0.082 |
| Risperidone Prolonged Release | Extrapyramidal Symptoms Rating Scale (ESRS) Total Score | Week 50 | 0.089 Units on a scale | Standard Error 0.086 |
Secondary
Global Assessment of Functioning (GAF) Scale Score
The GAF scale is a 100-point tool rating overall psychological, social and occupational functioning of adults. The higher score range (91-100) refers to a superior functioning in a wide range of activities, and absence of symptoms. The lower score range (1-10) refers to persistent danger of severely hurting self or others; or persistent inability to maintain minimum personal hygiene; or serious suicidal act with clear expectation of death.
Time frame: Screening, and Week 8, 16, 24, 38 and 50
Population: The ITTe population included all the Participants who received at least one dose of study medication and provided one measure post-baseline of efficacy.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Risperidone Prolonged Release | Global Assessment of Functioning (GAF) Scale Score | Screening | 62.6 Units on a scale | Standard Error 3.1 |
| Risperidone Prolonged Release | Global Assessment of Functioning (GAF) Scale Score | Week 8 | 67.5 Units on a scale | Standard Error 2.6 |
| Risperidone Prolonged Release | Global Assessment of Functioning (GAF) Scale Score | Week 16 | 72.5 Units on a scale | Standard Error 2.5 |
| Risperidone Prolonged Release | Global Assessment of Functioning (GAF) Scale Score | Week 24 | 71.4 Units on a scale | Standard Error 2.3 |
| Risperidone Prolonged Release | Global Assessment of Functioning (GAF) Scale Score | Week 38 | 73.9 Units on a scale | Standard Error 2.3 |
| Risperidone Prolonged Release | Global Assessment of Functioning (GAF) Scale Score | Week 50 | 68.6 Units on a scale | Standard Error 2.3 |
Secondary
Personal and Social Performance (PSP) Scale Score
The PSP scale assesses the degree of a participant's dysfunction (ranging from i \[absent\] to vi \[very severe) within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, disturbing and aggressive behavior. The overall score ranges from 1 to 100. Based on the 4-domains there was one total score. Participants with a score of 71 to 100 had a mild degree of difficulty; from 31 to 70, varying degrees of disability; participants with scores of 30 or less function so poorly as to require intensive supervision.
Time frame: Screening, and Week 8, 16, 24, 38 and 50
Population: The ITTe population included all the Participants who received at least one dose of study medication and provided one measure post-baseline of efficacy.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Risperidone Prolonged Release | Personal and Social Performance (PSP) Scale Score | Screening | 60.0 Units on a scale | Standard Error 2.9 |
| Risperidone Prolonged Release | Personal and Social Performance (PSP) Scale Score | Week 8 | 66.4 Units on a scale | Standard Error 2.4 |
| Risperidone Prolonged Release | Personal and Social Performance (PSP) Scale Score | Week 16 | 72.6 Units on a scale | Standard Error 2.3 |
| Risperidone Prolonged Release | Personal and Social Performance (PSP) Scale Score | Week 24 | 71.7 Units on a scale | Standard Error 2.1 |
| Risperidone Prolonged Release | Personal and Social Performance (PSP) Scale Score | Week 38 | 71.8 Units on a scale | Standard Error 2.1 |
| Risperidone Prolonged Release | Personal and Social Performance (PSP) Scale Score | Week 50 | 69.1 Units on a scale | Standard Error 2.2 |
Secondary
Short Form-36 (SF-36) - Quality of Life
The SF-36 is a survey of participant health. It consists of eight scaled scores, which are the weighted sums of the questions in their section. The eight sections are: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Each item is scored on a 0-100 range so that the lowest and highest possible scores are set at 0 and 100, respectively. All items are scored so that a high score defines a more favorable health state.
Time frame: Baseline and Week 50
Population: The ITTe population included all the Participants who received at least one dose of study medication and provided one measure post-baseline of efficacy.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Risperidone Prolonged Release | Short Form-36 (SF-36) - Quality of Life | Emotional Aspect : Week 50 | 55.0 Units on a scale | Standard Deviation 41.7 |
| Risperidone Prolonged Release | Short Form-36 (SF-36) - Quality of Life | Mental Health : Week 50 | 56.6 Units on a scale | Standard Deviation 20.6 |
| Risperidone Prolonged Release | Short Form-36 (SF-36) - Quality of Life | Vitality : Baseline | 53.8 Units on a scale | Standard Deviation 21.2 |
| Risperidone Prolonged Release | Short Form-36 (SF-36) - Quality of Life | Functional capacity : Baseline | 79.2 Units on a scale | Standard Deviation 21.4 |
| Risperidone Prolonged Release | Short Form-36 (SF-36) - Quality of Life | Physical aspect : Baseline | 48.2 Units on a scale | Standard Deviation 40.2 |
| Risperidone Prolonged Release | Short Form-36 (SF-36) - Quality of Life | Pain : Baseline | 73.7 Units on a scale | Standard Deviation 27.2 |
| Risperidone Prolonged Release | Short Form-36 (SF-36) - Quality of Life | Health General State : Baseline | 60.7 Units on a scale | Standard Deviation 18.4 |
| Risperidone Prolonged Release | Short Form-36 (SF-36) - Quality of Life | Social Aspect : Baseline | 56.1 Units on a scale | Standard Deviation 28 |
| Risperidone Prolonged Release | Short Form-36 (SF-36) - Quality of Life | Emotional Aspect : Baseline | 34.9 Units on a scale | Standard Deviation 38.4 |
| Risperidone Prolonged Release | Short Form-36 (SF-36) - Quality of Life | Mental Health : Baseline | 58.9 Units on a scale | Standard Deviation 21.9 |
| Risperidone Prolonged Release | Short Form-36 (SF-36) - Quality of Life | Functional capacity : Week 50 | 67.9 Units on a scale | Standard Deviation 31.6 |
| Risperidone Prolonged Release | Short Form-36 (SF-36) - Quality of Life | Physical aspect : Week 50 | 52.9 Units on a scale | Standard Deviation 41.3 |
| Risperidone Prolonged Release | Short Form-36 (SF-36) - Quality of Life | Pain : Week 50 | 75.4 Units on a scale | Standard Deviation 29.5 |
| Risperidone Prolonged Release | Short Form-36 (SF-36) - Quality of Life | Health General State : Week 50 | 62.7 Units on a scale | Standard Deviation 19.5 |
| Risperidone Prolonged Release | Short Form-36 (SF-36) - Quality of Life | Vitality : Week 50 | 53.1 Units on a scale | Standard Deviation 18.3 |
| Risperidone Prolonged Release | Short Form-36 (SF-36) - Quality of Life | Social Aspect : Week 50 | 59.9 Units on a scale | Standard Deviation 26.2 |